Regencor's team envisions a future where myocardial infarctions no longer impose incurable & life threatening tissue damage or progression to heart failure
Subcutaneous Sustained Delivery via Pump: A true game-changer in heart disease therapy
Our recombinant protein, delivered subcutaneously, reverses the formation of scar tissue. Scar tissue is the most serious complication after a myocardial infarction as it weakens the heart and leads to progressive heart failure.
Thomas Okarma, MD, PhD
Chairman, President & CEO
Pilar Ruiz-Lozano, PhD
Chief Scientific Officer
Mark Mercola, PhD